📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Solara Active Pharma Q3 Revenue Grows to ₹349 Cr; Net Loss Widens to ₹17.43 Cr
Solara Active Pharma reported a 16% YoY revenue growth to ₹349 crore for Q3 FY26, but the company's financial health remains under significant pressure. The net loss widened to ₹17.43 crore, impacted by a ₹6.75 crore exceptional item related to new labor codes. Concerns persist regarding liquidity as net current liabilities exceed assets by ₹92.44 crore, with accumulated losses reaching ₹329.64 crore. The company is banking on a pending ₹134.99 crore rights issue call to stabilize its capital position.
Key Highlights
Revenue from operations rose to ₹349.00 crore in Q3 FY26 from ₹300.31 crore in Q3 FY25.
Net loss for the quarter stood at ₹17.43 crore versus a profit of ₹8.09 crore in the previous year's corresponding quarter.
Exceptional loss of ₹6.75 crore recorded due to gratuity and compensated absences impact under new labor codes.
Net current liabilities exceed net current assets by ₹92.44 crore as of December 31, 2025.
Company plans to raise ₹134.99 crore through the final call of its pending rights issue to fund operations.
👀 What to Watch
Investors should exercise caution given the widening losses and the 'going concern' notes regarding liquidity and working capital deficits. The stock's recovery depends heavily on the successful completion of the rights issue and a significant turnaround in operational margins.
Solara Pharma Issues Second Reminder for ₹131.25 First Call Money Payment
Solara Active Pharma Sciences has issued a second reminder notice for the payment of the First Call Money related to its Rights Issue. Shareholders holding partly paid-up shares are required to pay ₹131.25 per share, which includes ₹3.50 towards face value and ₹127.75 towards premium. The payment window is scheduled from February 5, 2026, to February 19, 2026. Upon successful payment, shares will be converted from a paid-up value of ₹3.50 to ₹7.00.
Key Highlights
First Call Money amount is set at ₹131.25 per partly paid-up equity share
Payment period runs for 15 days from February 5, 2026, to February 19, 2026
Failure to pay will result in the forfeiture of shares and any amount already paid
Successful payment upgrades shares to ₹7.00 partly paid-up status under ISIN IN9624Z01022
Payments must be made electronically via the dedicated RTA portal using Net Banking or UPI
👀 What to Watch
Investors holding partly paid-up shares (ISIN: IN9624Z01014) must complete the payment by February 19, 2026, to prevent the forfeiture of their existing investment. Ensure the payment is made from the registered bank account to avoid rejection.
Solara Appoints Mohanraj S as Whole-Time Director for 3-Year Term
Solara Active Pharma Sciences has announced the appointment of Mr. Mohanraj S as an Additional Executive Director and Whole-Time Director, effective January 1, 2026. The appointment is for a three-year tenure and is subject to shareholder approval via postal ballot. Mr. Mohanraj brings over 30 years of extensive experience in industrial relations and workforce governance, having held senior roles at Mylan Laboratories and Tata Advanced Materials. His expertise in managing complex labor environments and regulatory compliance is expected to support the company's manufacturing operations.
Key Highlights
Appointment of Mr. Mohanraj S as Whole-Time Director for a fixed term of 3 years starting January 2026.
The appointee possesses over 30 years of experience across Pharma, Biotech, and Defence sectors.
Expertise includes negotiating 7-8 long-term union settlements, primarily in the pharmaceutical industry.
Mr. Mohanraj S is not related to any existing Directors or Key Managerial Personnel of the company.
👀 What to Watch
This is a strategic management appointment aimed at strengthening industrial relations and operational compliance. Investors should view this as a routine governance update with no immediate impact on stock valuation.
Solara Appoints Mr. Mohanraj S as Whole-Time Director for 3-Year Term
Solara Active Pharma Sciences has approved the appointment of Mr. Mohanraj S as an Additional Executive Director and Whole-Time Director, effective January 1, 2026. The appointment is for a three-year tenure and is subject to shareholder approval through a postal ballot. Mr. Mohanraj brings over 30 years of extensive experience in industrial relations and workforce governance, having previously held senior roles at Mylan Laboratories and Tata Advanced Materials. This move appears aimed at strengthening the company's manufacturing operations and labor management frameworks.
Key Highlights
Appointment of Mr. Mohanraj S as Whole-Time Director for a fixed term of 3 years
New leadership role becomes effective from January 1, 2026
Appointee brings over 30 years of experience across Pharma, Biotech, and Defense sectors
Proven track record with 7-8 successful long-term union settlements in the pharmaceutical industry
The board meeting concluded within 10 minutes, reflecting a focused agenda on this appointment
👀 What to Watch
Investors should view this as a routine leadership reinforcement aimed at operational stability. No immediate action is required, but the appointee's expertise in industrial relations may benefit long-term manufacturing efficiency.
Solara Active Pharma: Whole Time Director & COO Resigns, eff. Dec 31, 2025
Mr. Mohan Muthunarayanan has resigned from his position as Whole Time Director & Chief Operating Officer of Solara Active Pharma Sciences Limited, effective December 31, 2025. He is transitioning to the role of Chief Operating Officer at Synthix Global Pharma Solutions Limited, a wholly-owned subsidiary of Solara. His focus will be on developing the Polymers and CRAMs division and transforming the Vizag facility into a CDMO facility. The company acknowledged his valuable contributions during his tenure.
Key Highlights
Mr. Mohan Muthunarayanan resigns as Whole Time Director & COO effective December 31, 2025
DIN of Mr. Mohan Muthunarayanan is 03610282
He will be COO of Synthix Global Pharma Solutions Limited, a wholly owned subsidiary
ICSI Membership No. of Pooja Jaya Kumar is A57415
👀 What to Watch
Investors should monitor the transition and any potential impact on Solara's operations due to the change in leadership. Further updates on the company's strategy for the Polymers, CRAMs division, and Vizag facility are also worth watching.
